Henlius Presents New Studies At ISPOR Europe 2026 To Advance Treatment Value Assessment And Global Access
ISPOR Europe 2026 was held in Vienna, Austria, from November 8 to 11, 2026. As a leading international forum for health technology assessment (HTA) and health economics and outcomes research (HEOR), the conference brought together health policymakers, payer representatives, and leading experts from industry and academia worldwide. Henlius presented three studies as posters, focusing on key products in gastrointestinal and breast cancers, as well as global launch decision-making for innovative oncology medicines.
One study modeled the long-term health outcomes of serplulimab (HANSIZHUANG in China, Hetronifly in Europe), Henlius’ independently developed innovative anti-PD-1 monoclonal antibody, in patients with PD-L1-positive resectable gastric cancer. By quantifying the potential long-term health gains of its perioperative regimen compared with chemotherapy, the study provided health outcomes evidence to support pharmacoeconomic evaluation. Also presented were a methodological study proposing a multi-criteria decision analysis (MCDA) framework for global launch prioritization of innovative oncology medicines, and a study comparing the efficacy and safety of three China-developed pertuzumab biosimilars, including HLX11 (HANBEIYOU in China, POHERDY in the US and Europe), with reference pertuzumab. Together, these studies demonstrate Henlius’ continued efforts to advance medicine value assessment and global access through high-quality evidence.
Serplulimab: Quantifying Long-Term Health Benefits to Support Pharmacoeconomic Evaluation
Serplulimab is the world’s first and only* anti-PD-1 mAb globally approved for perioperative gastric cancer treatment. It was also the first** anti-PD-1 mAb approved as first-line treatment for extensive-stage small cell lung cancer (ES-SCLC). Currently, serplulimab has been approved globally*** for the treatment of squamous non-small cell lung cancer (sqNSCLC), ES-SCLC, esophageal squamous cell carcinoma (ESCC), non-squamous non-small cell lung cancer (nsqNSCLC), and gastric cancer (GC) indications. It has also shown anti-tumor potential in studies of limited-stage SCLC, colorectal cancer and other tumor types.
The approval of serplulimab for perioperative gastric cancer was primarily based on ASTRUM-006. The study results were first presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published online in The Lancet (IF: 88.5). ASTRUM-006 is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study enrolling 588 patients with PD-L1-positive (CPS ≥5), resectable, locally advanced gastric or gastroesophageal junction adenocarcinoma. In the PD-L1 CPS ≥5 population, the regimen of neoadjuvant serplulimab plus chemotherapy followed by adjuvant serplulimab monotherapy significantly prolonged event-free survival (EFS) versus the chemotherapy control group, reducing the risk of disease progression, recurrence, other new malignancies, or death by 33%, as assessed by blinded independent central review (BICR).
Building on evidence of clinical benefit, evaluating a treatment’s pharmacoeconomic value by considering both treatment costs and patients’ long-term health gains is key to advancing global access. The long-term health outcomes simulation study of perioperative serplulimab for gastric cancer, presented at ISPOR Europe 2026 (poster number: EE533) was led by Dr. Xiaoning He of Tianjin University. Using data from the Chinese population in ASTRUM-006, the researchers developed a semi-Markov model with a 10-year time horizon to compare the survival and quality-of-life benefits of perioperative serplulimab versus SOX chemotherapy in Chinese patients with PD-L1-positive, locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma. The model incorporated perioperative and subsequent treatments, combining survival time with quality of life across different health states to project the long-term health gains associated with each regimen.
Over the 10-year simulation period, the model projected that patients receiving perioperative serplulimab would spend an average of 5.72 years alive without recurrence or metastasis, compared with 4.61 years with perioperative SOX chemotherapy, a gain of 1.11 years. The study further combined survival and quality of life to assess health benefits, using one year of life in full health as the standard. The projected outcomes were 4.47 and 3.83 quality-adjusted life years (QALYs) per patient in the serplulimab and SOX groups, respectively. This represents an additional health benefit equivalent to 0.64 years of life in full health per patient with serplulimab.
The study also modeled a scenario in which both groups received the same treatment after their first recurrence or progression. Under this assumption, the projected outcomes were 4.53 and 3.83 QALYs per patient, respectively, representing an additional health benefit equivalent to 0.70 years of life in full health per patient with serplulimab. Under both assumptions for subsequent treatment, the model projected greater long-term health benefits with the perioperative serplulimab regimen.
By quantifying the projected long-term health gains of perioperative serplulimab compared with chemotherapy, the study provides a foundation for further pharmacoeconomic evaluation incorporating costs across the full course of treatment. The findings strengthen the evidence base for serplulimab’s long-term value and can support pharmacoeconomic assessments for national reimbursement in China.
Advancing Global Access and Strengthening a Diversified Product Portfolio
Bringing innovative medicines to patients worldwide requires consideration of patient needs, therapeutic value, and access conditions across countries and regions. As Henlius continues to build clinical and health economic evidence for its core products, the company is also advancing the global reach of its innovations.
To inform global launch strategy, Dr. Kalman E. Wijaya, Henlius’ Global Head of Value Access and Health Economics, conducted a methodological study on global launch prioritization (poster number: HTA101). The study proposed a preliminary multi-criteria decision analysis (MCDA) framework encompassing six domains: disease burden and unmet medical need; clinical differentiation and therapeutic value; health economic evidence and HTA readiness; pricing and reimbursement opportunity; healthcare-system access environment; and operational launch feasibility. The framework aims to support consistent and reproducible country launch prioritization for innovative oncology medicines.
A key component of Henlius’ diversified portfolio, HLX11 (HANBEIYOU in China, POHERDY in the U.S. and Europe) is an independently developed pertuzumab biosimilar approved in China, the U.S., and the EU. It is the first and only**** China-developed pertuzumab biosimilar approved outside China. Together with Henlius’ independently developed HANQUYOU (trastuzumab, HERCESSI™ in the U.S. and Zercepac in Europe), it forms the first**** China-developed trastuzumab–pertuzumab combination with approvals across all three markets, further strengthening the company’s portfolio for HER2-positive breast cancer.
Providing patients with more treatment options offering reliable efficacy and comparable safety is an important contribution of biosimilars. A comparative study presented at ISPOR Europe 2026 (poster number: CO20) was conducted by researchers including Dr.Chunlu Wang of the Center for Health Insurance and Health Services Research at the University of International Business and Economics, and Dr. Shiqi Li of Henlius. The study included Phase 3 registrational trials of three China-developed pertuzumab biosimilars, including HLX11. Researchers pooled efficacy and safety data comparing the biosimilars with reference pertuzumab and used reference pertuzumab as a common comparator for indirect comparisons among the biosimilars.
All three trials met their prespecified equivalence margins. The pooled analysis further supported comparable efficacy and similar safety between the biosimilars and reference pertuzumab. In indirect comparisons among the biosimilars, HLX11 showed favorable numerical trends on selected safety measures, although the differences were not statistically significant. These findings add clinical evidence supporting the three biosimilars as alternatives to reference pertuzumab in pertuzumab-containing dual HER2 blockade regimens.
Together, these studies extend from assessing the long-term health benefits of innovative oncology medicines to informing global launch and access decisions, while adding comparative evidence to support treatment choices. They reflect Henlius’ continued efforts to advance the value and global reach of innovative medicines through evidence-based research and expand treatment options with high-quality biologics. Guided by patient needs, Henlius will continue to deepen medicine value research and advance R&D innovation, clinical application, and global access to deliver more accessible and effective treatment options to patients worldwide
* In June 2026, serplulimab received NMPA approval as the world's first anti-PD-1 mAb for perioperative gastric cancer treatment. As of November 2026, it remains the only one.
** In January 2023, serplulimab received NMPA approval as the world's first anti-PD-1 mAb for the first line treatment of ES-SCLC.
*** Approved indications may vary by country or region. Please refer to announcements issued by local regulatory authorities for approved indications in each market.
****As of November 2026, based on the latest search results from the NMPA, FDA, and EMA.
Source: Shanghai Henlius Biotech, Inc